Zolpidem Tartrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318998

CAS#: 103188-50-7 (tartrate)

Description: Zolpidem is a prescription medication used for the treatment of insomnia and some brain disorders. This drug is a controlled substance and has been discontinued.

Chemical Structure

Zolpidem Tartrate
CAS# 103188-50-7 (tartrate)

Theoretical Analysis

MedKoo Cat#: 318998
Name: Zolpidem Tartrate
CAS#: 103188-50-7 (tartrate)
Chemical Formula: C42H48N6O8
Exact Mass:
Molecular Weight: 764.88
Elemental Analysis: C, 65.95; H, 6.33; N, 10.99; O, 16.73

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 99294-93-6 (tartrate)   82626-48-0 (free base)   103188-50-7 (tartrate)    

Synonym: SL 80.0750; SL-800750-23-N; Zolpidem Tartrate. brand names Ambien, Ambien CR, Intermezzo, Stilnox, Stilnoct, Sublinox, Hypnogen, Lunata, Zonadin, Sanval, Zolsana and Zolfresh

IUPAC/Chemical Name: N,N-dimethyl-2-(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)acetamide;((2R,3R)-2,3-dihydroxysuccinate) (2:1)


InChi Code: InChI=1S/2C19H21N3O.C4H6O6/c2*1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19;5-1(3(7)8)2(6)4(9)10/h2*5-10,12H,11H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)/t;;1-,2-/m..1/s1

SMILES Code: O=C(N(C)C)CC1=C(C2=CC=C(C)C=C2)N=C3C=CC(C)=CN31.O=C(N(C)C)CC4=C(C5=CC=C(C)C=C5)N=C6C=CC(C)=CN64.O=C(O)[C@H](O)[C@@H](O)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 764.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Martinez-Ramirez D, Paz-Gomez V, Rodriguez RL. Response to zolpidem in oromandibular dystonia: a case report. Parkinsonism Relat Disord. 2015 Feb;21(2):154-5. doi: 10.1016/j.parkreldis.2014.11.006. Epub 2014 Nov 20. Review. PubMed PMID: 25443554.

2: Stranks EK, Crowe SF. The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol. 2014;36(7):691-700. doi: 10.1080/13803395.2014.928268. Epub 2014 Jun 16. Review. PubMed PMID: 24931450.

3: Pergolizzi JV Jr, Taylor R Jr, Raffa RB, Nalamachu S, Chopra M. Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness. Sleep Disord. 2014;2014:527109. doi: 10.1155/2014/527109. Epub 2014 Feb 5. Review. PubMed PMID: 24649369; PubMed Central PMCID: PMC3932650.

4: Fitzgerald AC, Wright BT, Heldt SA. The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors. Psychopharmacology (Berl). 2014 May;231(9):1865-96. doi: 10.1007/s00213-014-3457-x. Epub 2014 Feb 22. Review. PubMed PMID: 24563183.

5: Victorri-Vigneau C, Gérardin M, Rousselet M, Guerlais M, Grall-Bronnec M, Jolliet P. An update on zolpidem abuse and dependence. J Addict Dis. 2014;33(1):15-23. doi: 10.1080/10550887.2014.882725. Review. PubMed PMID: 24467433.

6: Gosseries O, Charland-Verville V, Thonnard M, Bodart O, Laureys S, Demertzi A. Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness. Curr Pharm Des. 2014;20(26):4167-84. Review. PubMed PMID: 24025057.

7: Yang LP, Deeks ED. Sublingual zolpidem (Edluar™; Sublinox™). CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y. Review. PubMed PMID: 23034583.

8: Low-dose sublingual zolpidem (Intermezzo) for insomnia due to middle-of-the-night awakening. Med Lett Drugs Ther. 2012 Apr 2;54(1387):25-6. Review. PubMed PMID: 22469649.

9: Foda NH, Ali SM. Zolpidem tartrate. Profiles Drug Subst Excip Relat Methodol. 2012;37:413-38. doi: 10.1016/B978-0-12-397220-0.00011-8. Epub 2012 Mar 19. Review. PubMed PMID: 22469325.

10: Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother. 2012 Apr;13(6):879-93. doi: 10.1517/14656566.2012.667074. Epub 2012 Mar 19. Review. PubMed PMID: 22424586.

11: Zolpidem oral spray (zolpimist) for insomnia. Med Lett Drugs Ther. 2012 Feb 20;54(1384):14-5. Review. PubMed PMID: 22354280.

12: Staner L, Danjou P, Luthringer R. A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia. Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197. Review. PubMed PMID: 22288669.

13: Daley C, McNiel DE, Binder RL. "I did what?" Zolpidem and the courts. J Am Acad Psychiatry Law. 2011;39(4):535-42. Review. PubMed PMID: 22159981.

14: Dang A, Garg A, Rataboli PV. Role of zolpidem in the management of insomnia. CNS Neurosci Ther. 2011 Oct;17(5):387-97. doi: 10.1111/j.1755-5949.2010.00158.x. Epub 2010 Jun 11. Review. PubMed PMID: 20553305.

15: Kovacic P, Somanathan R. Zolpidem, a clinical hypnotic that affects electronic transfer, alters synaptic activity through potential GABA receptors in the nervous system without significant free radical generation. Oxid Med Cell Longev. 2009 Jan-Mar;2(1):52-7. Review. PubMed PMID: 20046645; PubMed Central PMCID: PMC2763231.

16: Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med. 2009 Aug 15;5(4):377-83. Review. PubMed PMID: 19968019; PubMed Central PMCID: PMC2725260.

17: Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009 Oct 15;5(5):471-6. Review. PubMed PMID: 19961034; PubMed Central PMCID: PMC2762721.

18: Myslobodsky M. The paradox of caffeine-zolpidem interaction: a network analysis. Curr Drug Targets. 2009 Oct;10(10):1009-20. Review. PubMed PMID: 19860644.

19: Owen RT. Novel zolpidem formulations. Drugs Today (Barc). 2009 May;45(5):395-400. doi: 10.1358/dot.2009.45.5.1370457. Review. PubMed PMID: 19584967.

20: Bogan RK. Treatment options for insomnia--pharmacodynamics of zolpidem extended-release to benefit next-day performance. Postgrad Med. 2008 Sep;120(3):161-71. doi: 10.3810/pgm.2008.09.1916. Review. PubMed PMID: 18824834.

Additional Information

Related CAS#
99294-93-6 (Tartrate); 82626-48-0 (free base)